Adapta Medical receives FDA market clearance for touchless urinary catheter

Adapta Medical, Inc. has received FDA market release for the PerfIC Cath® intermittent touchless urinary catheter. The sterile catheter system was designed by J. Glen House, MD, a C7 quadriplegic with limited finger dexterity.

FDA clearance for the PerfIC Cath® will result in Adapta expanding the PerfIC Cath® product line and launching the new mPower Cath™ series catheter product line. Both product lines feature hydrophilic and gel lubricants for straight and coude-tipped catheters. The PerfIC Cath® catheters have an attached urine collection bag while the mPower Cath™ products have a urine collection bag that is not attached to the catheter.

"The PerfIC Cath® catheter represents a significant advancement in intermittent catheter technology and is extremely easy to use, even with limited dexterity," said House. "It is designed for those with a spinal cord injury, multiple sclerosis, diabetes, stroke, spina bifida or other conditions that require a catheter, but can be used easily by those with normal hand dexterity too. It is created for users by users." With a variety of patents, the catheters are truly unique and offer a new experience for catheter users.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How can microdialysis benefit drug development?